The effects of exogenous histamine on nasal mucosal blood flow and the systemic activity of intranasally administered desmopressin, a vasopressin analogue, were studied in normal volunteers. Ten subjects received either saline or histamine (1, 20, 100, and 500 micrograms) by intranasal spray. Maximal nasal mucosal blood flow response, determined by laser doppler velocimetry, demonstrated a significant (P less than 0.05) linear relationship to histamine dose. Eight additional subjects received each of the following intranasal treatments: 20 micrograms histamine followed by 10 micrograms desmopressin; normal saline followed by 10 micrograms desmopressin; 20 micrograms histamine followed by vehicle; or normal saline and vehicle. Nasal blood flow was determined before and after each treatment. Desmopressin activity was assessed by measuring urine osmolality, flow rate, electrolyte, and creatinine concentration for 24 h after each treatment. The effect of histamine and desmopressin was greater than desmopressin alone, with respect to nasal blood flow response (103 +/-24 vs. 4 +/-17%, mean +/-SEM, P less than 0.02), initial urine osmolality (520 +/-123 vs. 333 +/-75 mosM, P less than 0.03), urine electrolyte (potassium, 45 +/-11 vs. 28 +/-7 meq/liter; sodium, 68 +/-21 vs. 36 +/-8 meq/liter, P less than 0.03) and creatinine concentrations (95 +/-23 vs. 60 +/-13 mg/dl, P less than 0. 
Introduction
Nasal mucosal blood flow is regulated by complex neurophysiological mechanisms, and is responsive to numerous physiological (1), pharmacological (2) (3) (4) (5) , and environmental stimuli (6) . Previous reports (2-5, 7, 8) have described the effects of various pharmacologic agents on nasal blood flow; however, there is no information available regarding the effect of nasal blood flow on the transport of drugs administered topically to the nasal mucosa in the form ofsprays or aerosols. Low molecular weight, lipophilic drugs, such as propranolol (9) and progesterone (10) , demonstrate high nasal mucosal permeability that results in 100% absorption, which is presumably unin-fluenced by nasal blood flow. For higher molecular weight, peptidic drugs, where maximal absorption is generally less than 10% (11) , nasal blood flow may be a limiting factor. A potential means of enhancing nasal peptide absorption would be the administration of substances capable ofincreasing nasal blood flow. In theory, by increasing nasal blood flow, concentrations of drug on the basal side of the nasal mucosal membrane would remain low, increasing the effective concentration gradient, thereby augmenting peptide membrane permeation by passive diffusion.
The current study was designed to measure the nasal blood flow response ofnormal subjects to varying doses ofexogenous histamine, a vasodilator, and to test the hypothesis that the systemic activity of an intranasally delivered peptide drug, desmopressin, would be enhanced by increasing nasal mucosal blood flow. Desmopressin acetate [1-(3-mercaptopropionic acid)-8-D-arginine vasopressin, monoacetate salt], a vasopressin analogue administered intranasally for the treatment of neurogenic diabetes insipidus (12) , has an estimated intranasal bioavailability of 4-5% (13) . In these experiments nasal blood flow was measured by laser doppler velocimetry and desmopressin activity was assessed by determining the effect of the drug on urine volume flow, osmolality, and electrolyte and creatinine concentrations in water-loaded normal volunteers. Methods Subjects and study design. A total of 18 non-smoking normal volunteers participated in two separate experiments. They were evaluated by medical history, physical and laboratory examinations, and gave their informed consent. Specifically, subjects were excluded from study if they had a history ofany allergic reactions, asthma, chronic sinusitis or rhinitis, or physical or laboratory (eosinophilia on peripheral blood smear) evidence of existing allergies, upper airway disease, or other inflammation ofnasal mucosal membranes. Allergy skin tests were not performed and nasal eosinophilia was not excluded. All subjects tested were required to have anatomically acceptable nasal passages for testing and subjects with deviated or perforated septums or nasal polyps were excluded. Normal renal function was assessed by the determination of serum creatinine and blood urea nitrogen, standard urinalysis and microscopic examination on screening visits, and the determination of creatinine clearance for the 12-h period before the first day of dosing. The subjects took no medications other than study drugs from 15 d before the first dosing through the completion of the study.
The first experiment measured nasal blood flow response to graded doses ofexogenous histamine. 10 volunteers were studied (nine males, one female), 20-44 years old (mean, 28 yr), weighing 53.8-90.5 kg (mean, 72.2 kg). Each subject received five different, randomly assigned, double-blinded treatments (normal saline, 1, 20, 100, and 500 gg histamine), one treatment each day. After resting in a supine position for 30 min to allow for ambient temperature and activity equilibrations, each subject underwent a 5-min baseline determination of nasal blood flow. The subject then received one of the four histamine doses or vehicle. Each treatment was administered to a single nostril and the same nostril was used throughout the experiment. Dosing time was 20 s or less. Nasal blood flow was remeasured immediately after dosing was complete for a total of 10 min. The subject remained supine during the dosing and throughout the 10-min post-dosing measurement sequence. Percent change in nasal blood flow from baseline was calculated as the difference between the maximum sustained postdose and predose readings, divided by the predose reading. A maximum sustained reading was defined as the highest postdose value of nasal blood flow, which was constant for 15 s or greater in duration. Transient variations or fluctuations due to swallowing or movement by the patients were duly marked as artifacts on the recording and disregarded. The same procedure was repeated on each of the five dosing days.
The second experiment was designed to measure the effect of intranasal histamine on the nasal absorption of desmopressin. Eight different healthy, male volunteers were studied, 18-38 yr old (mean, 25.1 yr), 60.9-97.5 kg in weight (mean, 88.2 kg). The eight volunteers entered into a randomized four-way crossover, double-blinded study design. The four treatments were: (I) normal saline followed by desmopressin vehicle (5.0 mg/ml chlorobutanol in normal saline adjusted to pH 4.0 with HCl acid); (II) active histamine (20 ,g) followed by desmopressin vehicle; (III) normal saline followed by active desmopressin (10 jg); and (IV) active histamine (20 Mug) followed by active desmopressin (10 jg).
Subjects fasted 10 h before, and 4 h after dosing for each ofthe four treatment regimens. They received isocaloric, caffeine-free meals consisting of 15% protein, 50% carbohydrates, and 35% fat, with adjusted sodium and potassium intakes of 60 and 40 meq/l,000 cal, respectively. Distilled water, 15.2 ml/kg body weight, for oral water loading was given 1 h before dosing to suppress endogenous antidiuretic hormone secretion. The subjects drank additional quantities of distilled water every 2 h after dosing for the first 12 h, equal to their preceding 2-h urinary output. Urinary output was recorded every 2 h for the first 12 h followed by a 12-h collection. Nasal mucosal blood flow was measured by laser doppler velocimetry for 2 min before dosing (baseline) and immediately after dosing for 10 min. The 2-min determination of baseline flow was adequate, as minimal fluctuations occurred after stable probe placement was established and these fluctuations were identical to that observed in the 5-min baseline measurements performed in earlier histamine dose-response experiments. As in the first experiment, treatment phases were separated by 24 h and aerosols were applied to the same nostril at the same time on each experimental day.
Study medications. Histamine solutions were prepared from a commercial preparation of 1.0 mg histamine base/ml, without preservative (Histamine phosphate, Sterile Ampoule No. 269; Eli Lilly & Co., Indianapolis, IN). Desmopressin was utilized as commercially available DDAVP (USV Laboratories, Tarrytown, NY). The desmopressin vehicle contained chlorobutanol (5.0 mg/ml), sodium chloride (9 mg/ml), and hydrocloric acid (pH adjusted to 4.0) in identical amounts as the commercial desmopressin preparation. Study drugs were administered as 0. l-ml solutions by a hand-held nebulizer. In the second experiment, the histamine, or normal saline, was administered first, and was followed 30 s later by desmopressin, or vehicle. The nebulizer, powered by a Dyna-Vac (model 3; Cole-Parmer Instrument Co., Chicago, IL) compressor pump, emptied 100% of the volume, as measured by weighing the system before and after use. Sprayer volumes were measured by the use ofcalibrated syringes accurate to 0.005 ml. The nebulizer delivered an aerosol mist with a particle size of 2.1±2.5 gM (mean±SD), with 90.6±1.3% of the delivered particles measuring < 7.5 ,m in diameter as determined by five trial runs. Particle size was quantitated by the use of an aerosol particle monitor which sized and counted the particles by detecting their light-scattering profile on a photomultiplier (14) . During the 10-s spraying into the naris, the subject held his breath to minimize drug deposition beyond the nasal cavity. (27±8%, P < 0.04). Subjective local responses to the histamine administration included nasal congestion in three subjects, and a sensation of nasal burning in one subject, all at the 500-,gg dose. There were no complaints of sneezing, itching, or rhinorrhea. A total of four subjects reported headaches after doses of 1, 20, or 100 .g histamine. All symptoms were rated by the subjects as mild in intensity.
In the second experiment, the administration of active desmopressin alone (treatment III) significantly depressed (P <0.05) nasal blood flow response (4±17%) compared with treatment 1 (75±25%), normal saline and desmopressin vehicle (Fig. 2) . The intranasal administration of 20 ,g histamine before desmopressin (treatment IV) produced a nasal blood flow response (103±24%) that was significantly higher (P < 0.02) than after desmopressin alone and comparable in magnitude to that produced by the combined vehicles (Fig. 2) . Complaints related to treatments containing active histamine (treatments II and IV) were limited to headache in one subject (for both treatments) and nasal congestion in one subject (treatment IV).
Compared to vehicle (treatment I), urine osmolality was significantly increased (P < 0.05) for 6 h after either treatment with desmopressin alone (treatment III) or histamine and desmopressin (treatment IV) (Fig. 3) . Urine osmolality was significantly higher (P < 0.03) during the initial 2-h collection period after the combined administration of histamine and desmopressin (520±123 mosM) compared with desmopressin alone (333±75 mosM). Urine flow rate (Fig. 4) after desmopressin alone was significantly decreased (P < 0.05) for 6 h compared with saline and vehicle treatment, whereas the combination of histamine and desmopressin decreased (P < 0.05) urine flow rate for a total of 8 h. techniques, n = 8. Treatments: I, saline followed by vehicle; II, histamine followed by vehicle; III, saline followed by desmopressin; IV, histamine followed by desmopressin. ** Greater than treatment III (P < 0.02); * Less than treatment I (P < 0.05). Values expressed as mean±SEM. Collection Intervals (hours) Figure 3 . Urine osmolality response (milliosmolar per kilogram H20). Response to treatments: (o) saline followed by vehicle; (m) saline followed by desmopressin; (i) histamine followed by desmopressin. Arrow indicates time of oral water loading; mean±SEM values, n = 8. * Greater than saline and vehicle (P < 0.05). + Greater than desmopressin alone (P < 0.03). Treatment with histamine alone not different than saline and vehicle (not shown).
urine volume was significantly decreased (P < 0.03) compared with saline and vehicle treatment (4.1±0.64 liter) after histamine and desmopressin (3.0±0.52 liter) but not with desmopressin alone. Histamine alone (treatment II, not shown in Figs. 3 or 4) had no effect on either urine osmolality or flow rate in these subjects. The ability of histamine to acutely enhance the urine concentrating activity of desmopressin was also evidenced by the increases in urinary electrolyte and creatinine concentrations (Figs. 5-7) . For the initial 2-h collection period, the effect of treatment with histamine and desmopressin was greater than with desmopressin alone, with respect to urine potassium (45±11 vs. 28±7 meq/liter, P < 0.03), sodium (68±21 vs. 36±8 meq/liter, P < 0.03), and creatinine (95±23 vs. 60±13 mg/dl, P < 0.03) concentrations. During the subsequent two collection periods (2-4 and 4-6 h), both treatments induced equivalent increases in the concentration of urinary potassium, sodium, and creatinine, compared with saline and vehicle. Histamine alone had no effect on urinary electrolyte or creatinine concentrations. Collection Intervals (hours) Figure 5 . Urinary potassium concentration (milliequivalents per liter). Response to treatments: (o) saline followed by vehicle; (m) saline followed by desmopressin; (m) histamine followed by desmopressin, mean±SEM values, n = 8. * Greater than saline and vehicle (P < 0.05). t Greater than desmopressin alone (P < 0.03). Treatment with histamine alone not different than saline and vehicle (not shown). Collection Intervals (hours) Figure 7 . Urinary creatinine concentration (milligrams per deciliter). Response to treatments: (o) saline followed by vehicle; (-) saline followed by desmopressin; (X) histamine followed by desmopressin, mean±SEM values, n = 8. * Greater than saline and vehicle (P < 0.05). t Greater than desmopressin alone (P < 0.03). Treatment with histamine alone not different than saline and vehicle (not shown).
Discussion
Methodologies for evaluating nasal blood flow in humans include 133Xe washout (5), hydrogen clearance (19) , thermal clearance (20) , and laser doppler velocimetry techniques (6, 17) . The first two methods involve invasive procedures and measure overall mean flow rather than local or superficial nasal blood flow. The thermal clearance technique, due to its design, is inherently sensitive to local environmental conditions oftemperature and humidity and may be affected by any air movement in the nose. The laser doppler technique offers the advantages of continuous flow measurements, is noninvasive by design, and is capable of measuring superficial (mucosal) flow rates with appropriate equipment design. In addition, laser doppler flow measurements were shown not to vary when taken from the point of contact at the nasal mucosa and up to a distance of 3.5 mm from the mucosal surface (6). In the first experiment, we demonstrated a linear increase (P < 0.05) in the percent change in nasal blood flow, as measured by laser doppler velocimetry, in response to increasing doses of intranasal histamine. Previous work by Bende et al. (21) showed that nasal blood flow, as measured by 133Xe washout techniques, was increased by 71% after injection of20 gg histamine into the mucosa of the nasal inferior turbinate of normal sub- jects. Other exogenous vasoactive substances such as leukotriene D4 (2), and prostaglandin El (3) , have also been shown to directly increase nasal blood flow in human subjects. Similarly in the cat, the beta adrenergic agonists isoproterenol and terbutaline produced vasodilation (22) . The mechanism by which histamine exerts its action on local nasal blood flow is unknown but may be related to capillary dilation mediated by both HI and H2 receptors, both of which have been demonstrated in the blood vessels ofthe nasal mucosa (23) . Stimulation of the vascular HI receptor, with higher relative affinity for histamine, typically produces a more rapid, less sustained, vasodilatory response (24) similar to that observed in the current experiment. In the current experiments, the general lack of subjective complaints or visual evidence of mucosal edema would suggest that the response observed was not due to local irritant effects.
Our findings in the second experiment indicated that the prior intranasal application of 20 Aig histamine in normal subjects increased nasal blood flow, compared with desmopressin alone, and enhanced the antidiuretic activity of intranasal desmopressin. The effect of 10 ,ug desmopressin in reducing urine flow rate was significantly prolonged by the addition of histamine, and its early effect in increasing urinary osmolality, and electrolyte and creatinine concentration was potentiated. Although not significantly different, urine osmolality values were consistently higher from 2 to 8 h after combined administration of histamine and desmopressin, compared with desmopressin treatment alone. That this effect was not more pronounced may be due to the experimental conditions used, in that the subjects had probably attained maximal urine concentrating capacity in their water-loaded state. Our decision to use the 20-,gg histamine dose in these experiments was based on the nasal blood flow response profile in the first experiment, and the previous report by Bende et al. (21) , who found this dose to produce a significant increase in blood flow by 1 33Xe washout techniques.
Although we were unable to measure actual desmopressin plasma levels, out findings are consistent with the hypothesis that histamine enhanced desmopressin activity by increasing its absorption through the nasal mucosa. Hammer and Vilhardt (25) have previously demonstrated a direct correlation between peak desmopressin levels and the duration of its anti-diuretic action. Other reports (26, 27) (29) . Electron microscopy demonstrated horse radish peroxidase reaction products in the intercellular spaces of the tracheal epithelium, without an attendant increase in intracellular vessicular transport, suggesting that the effect of histamine was to increase the leakiness of the intercellular tight junctions. The histamine doses used in the above references were 150 to 500 times higher than those in our desmopressin experiments, and thus the permeability increases observed may be the result of mucosal injury rather than a physiological increase in membrane transport (30) . In the above studies, no consideration was given to the effect of these large doses of histamine on mucosal blood flow. It has also been shown that the intracellular tight junctions of nasal epithelium from patients with non-atopic chronic sinusitis or allergic rhinitis are relatively "leaky" to horseradish peroxidase, but that no intracellular protein uptake occurs (31) . In the current study, we did not assess the effects of histamine on epithelial cell morphology; however, it is unlikely that the small histamine doses administered affected mucosal integrity. Additionally, the brief duration of the nasal blood flow response, observed after histamine administration in the current experiment, would suggest an HI receptor-mediated mechanism rather than an H2 receptor-activated change in epithelial permeability. If in fact the absorption of intranasally administered peptide drugs can be enhanced by augmenting nasal blood flow, this approach may offer a means ofimproving the delivery and therapeutic efficacy of a number of higher molecular weight peptidic drugs including various hormonal agents.
In conclusion, nasal blood flow increased in a linear fashion with increasing doses of intranasal histamine. The administration of histamine immediately before desmopressin increased nasal blood flow response compared with desmopressin alone, and enhanced the antidiuretic action of this vasopressin analogue, presumably by increasing its absorption across the nasal membrane. In their ability to increase nasal blood flow, histamine, and similar physiological modifying agents, may promote the transnasal passage ofdrugs of limited mucosal permeability, such as biologically active peptides.
